In patients with human immunodeficiency virus 1, a comparison of the genotype of rebounding virus to that in the latent reservoir after highly active anti-retroviral therapy is discontinued indicates that the latent reservoir is not the cause of viral rebound in most cases. However, the precise anatomic location of the source of viral rebound is still undefined (pages 757–761).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins
Clinical Epigenetics Open Access 05 February 2018
-
Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells
Retrovirology Open Access 06 February 2017
-
Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage
Retrovirology Open Access 09 April 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Perelson, A.S. et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188– 191 (1997).
Chun, T.W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183 –188 (1997).
Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).
Zhang, L. et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340, 1605–1613 (1999).
Furtado, M.R. et al. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340, 1614–1622 ( 1999).
Davey, R.T., Jr. et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96, 15109–15114 (1999).
Chun, T.W. et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy . Nature Med. 6, 757–761 (2000).
Ho, D.D. Toward HIV eradication or remission: the tasks ahead. Science 280, 1866–1867 (1998).
Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med 5, 512– 517 (1999).
Ramratnam, B. et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nature Med. 6, 82–85 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ho, D., Zhang, L. HIV-1 rebound after anti-retroviral therapy. Nat Med 6, 736–737 (2000). https://doi.org/10.1038/77447
Issue Date:
DOI: https://doi.org/10.1038/77447
This article is cited by
-
Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins
Clinical Epigenetics (2018)
-
Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells
Retrovirology (2017)
-
Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage
Retrovirology (2010)
-
Neurobiology of Multiple Insults: HIV-1-Associated Brain Disorders in Those Who Use Illicit Drugs
Journal of Neuroimmune Pharmacology (2006)
